Management of Antipsychotic Therapy in Patients with Schizophrenia
DOI:
https://doi.org/10.6000/1929-6029.2025.14.24Keywords:
Antipsychotic therapy, schizophrenia, rationality of therapy, clinical compliance, side effectsAbstract
Antipsychotic therapy is the main approach in the treatment of schizophrenia, but there is often irrational use due to inappropriate drug selection, inappropriate dosage, and long-term use without evaluation. Factors that support therapeutic rationality include adherence to clinical guidelines, selection of safer antipsychotics, and optimal management of side effects. Therefore, it is important to evaluate the factors that contribute to rational and irrational therapy in the use of antipsychotics in patients with schizophrenia. This study aims at antipsychotic medication management and factors that cause irrational therapy, as well as evaluating factors that support therapeutic rationality in the use of antipsychotics in schizophrenic patients. This study used a cross-sectional study design involving schizophrenia patients undergoing antipsychotic therapy in a psychiatric hospital. Data were collected through patient medical records and interviews with health workers. Quantitative data were analyzed using descriptive statistics and inferential tests, including chi-square and regression analysis, to determine the association between patient characteristics and antipsychotic selection as well as therapy rationality. The results showed that 26.7% of patients received irrational therapy, with the main causes being inappropriate drug selection (45%), inappropriate dosage (30%), and long-term use without evaluation (25%). Meanwhile, 73.3% of patients received rational therapy, with the main contributing factors being adherence to clinical guidelines (50%), selection of safer antipsychotics (30%), and good side effect management (20%). Irrational antipsychotic therapy remains a significant problem in the management of schizophrenia. Adherence to clinical guidelines and appropriate therapy selection can improve treatment effectiveness and reduce the risk of side effects. Regular evaluation and a multidisciplinary approach are needed to improve the rationality of antipsychotic therapy.
References
Gaebel W, Rössler W, Sartorius N, (Eds.) The stigma of mental illness — End of the story? Springer International Publishing/Springer Nature 2017. DOI: https://doi.org/10.1007/978-3-319-27839-1
Lähteenvuo M, Tiihonen J. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. Drugs 2021; 81(11): 1273-1284. DOI: https://doi.org/10.1007/s40265-021-01556-4
Kule M, Kaggwa MM. Adherence to Typical Antipsychotics among Patients with Schizophrenia in Uganda: A Cross-Sectional Study. Schizophr Res Treatment 2023; 2023: 7035893. DOI: https://doi.org/10.1155/2023/7035893
Agrawal R, Rath B. Effectiveness Study of Typical and Atypical Antipsychotics on Patients with Schizophrenia using WHO Disability Assessment Schedule (WHODAS 2.0). Biomed Pharmacol J 2021; 14(3). DOI: https://doi.org/10.13005/bpj/2217
Kim S, Kim E. Current advances in pharmacotherapy for schizophrenia. Journal of the Korean Medical Association 2024; 67(2): 96-102. DOI: https://doi.org/10.5124/jkma.2024.67.2.96
Barliana MI, Ramdini DA, Afifah NN, Alfian SD, Sumiwi SA. Investigating the Effect of Adherence to Antipsychotic Thera-py on the Length of Stay and Number of Hospitalizations in Patients with Schizophrenia – A Descriptive Analysis. Patient Preference and Adherence 2024; 17: 2737-2747. DOI: https://doi.org/10.2147/PPA.S430083
Giordano GM, Bucci P, Mucci A, Pezzella P and Galderisi S (2021) Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. Front Psychiatry 12: 789179. DOI: https://doi.org/10.3389/fpsyt.2021.789179
Eranti SV, MacCabe JH, Bundy H, Murray RM. Gender difference in age at onset of schizophrenia: a meta-analysis. Psychological Medicine 2013; 43(1): 155-167. DOI: https://doi.org/10.1017/S003329171200089X
Wang S, Rhijn JV, Akkouh I, et al. Loss-of-function variants in the schizophrenia risk gene SETD1A alter neuronal network activity in human neurons through the cAMP/PKA pathway. Cell Rep 2022; 39(5): 110790. DOI: https://doi.org/10.1016/j.celrep.2022.110790
Baumann P, Bauknecht P, Kuzin M, Schoretsanitis G. Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review. Int J Psychiatry Clin Pract 2023; 27(4): 367-384. DOI: https://doi.org/10.1080/13651501.2023.2231047
Xin Li, Wanyan Zhou, Zhenghui Yi. A glimpse of gender differences in schizophrenia: General Psychiatry 2022; 35: e100823. DOI: https://doi.org/10.1136/gpsych-2022-100823
Rotstein A, Shadmi E, Roe D, Gelkopf M, Levine SZ. Gender differences in quality of life and the course of schizophrenia: national study. BJPsych Open 2022; 8(2): e35. DOI: https://doi.org/10.1192/bjo.2022.3
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global epidemiology and burden of schizophrenia: Findings from the Global Burden of Disease Study 2016. Schizophrenia Bulletin 2018; 44(6): 1195-1203. DOI: https://doi.org/10.1093/schbul/sby058
Stroup TS, Olfson M, Huang C, et al. Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia. JAMA Psychiatry 2021; 78(6): 632-641. DOI: https://doi.org/10.1001/jamapsychiatry.2021.0042
Bourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term effects of COVID-19 on mental health: A systematic review. J Affect Disord 2022; 299: 118-125. DOI: https://doi.org/10.1016/j.jad.2021.11.031
Lewine R, Hart M. Schizophrenia spectrum and other psychotic disorders. Handb Clin Neurol 2020; 175: 315-333. DOI: https://doi.org/10.1016/B978-0-444-64123-6.00022-9
Pardiñas AF, Smart SE, Willcocks IR, et al. Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. JAMA Psychiatry 2022; 79(3): 260-269. DOI: https://doi.org/10.1001/jamapsychiatry.2021.3799
Gómez-Revuelta M, Pelayo-Terán JM, Vázquez-Bourgon J, et al. Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial. Eur Neuropsychopharmacol 2021; 47: 74-85. DOI: https://doi.org/10.1016/j.euroneuro.2021.02.009
McWhinney SR, Brosch K, Calhoun VD, et al. Obesity and brain structure in schizophrenia - ENIGMA study in 3021 individuals [published correction appears in Mol Psychiatry 2022; 27(9): 3738. [published correction appears in Mol Psychiatry 2024; 29(1): 56. Mol Psychiatry 2022; 27(9): 3731-3737. DOI: https://doi.org/10.1038/s41380-022-01696-3
Pankova OF, Kazin NM, Ivanova SM. Schizophrenia spectrum disorders in children and adolescents: prevalence and diagnostics. Bulletin of RSMU 2021; (3): 75-8. DOI: https://doi.org/10.24075/brsmu.2021.022
Incekara F, Blom JD. Carl Jung: a life on the edge of reality with hypnagogia, hyperphantasia, and hallucinations. Front Psychol 2024; 15: 1358329. DOI: https://doi.org/10.3389/fpsyg.2024.1358329
Šulskutė R, Galnaitytė S, Usonytė I. Paranoid Schizophrenia: Case Report. Health Sciences 2023; 33(3): 58-59. DOI: https://doi.org/10.35988/sm-hs.2023.085
Fovet T, Plancke L, Amariei A, et al. Mental disorders on admission to jail: A study of prevalence and a comparison with a community sample in the north of France. Eur Psychiatry 2020; 63(1): e43. DOI: https://doi.org/10.1192/j.eurpsy.2020.38
Krakowski M, Tural U, Czobor P. The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol. The American Journal of Psychiatry 2021; 178(3): 266-274. DOI: https://doi.org/10.1176/appi.ajp.2020.20010052
Stuhec M. Antipsychotic treatment in elderly patients on polypharmacy with schizophrenia. Curr Opin Psychiatry 2022; 35(5): 332-337. DOI: https://doi.org/10.1097/YCO.0000000000000808
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
